Treatment of TH-MYCN transgenic mice with the ODC inhibitor α-difluoromethylornithine (DFMO) prevents oncogenesis in hemizygous mice, while delaying tumor development in homozygous mice. This evidence concerns the gene MYCN and neoplasm.